How a risk management programme can ensure safety in thalidomide use

Pharmaceutical Journal

Volumn 272, Issue 7286, 2004, Pages 190-191

  Thomson, David ^a   Capstick, Toby ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; DOFETILIDE; ISOTRETINOIN; THALIDOMIDE;

ACNE; ARTICLE; BIRTH DEFECT; CARDIOTOXICITY; CONSTIPATION; DRUG EFFICACY; DRUG FATALITY; DRUG MARKETING; DRUG SAFETY; ERYTHEMA NODOSUM LEPROSUM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH SURVEY; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; LICENSING; MEDICAL SPECIALIST; MULTIPLE MYELOMA; NEUROPATHY; PATIENT EDUCATION; PHARMACIST; PHOCOMELIA; PHYSICIAN; PREGNANCY DISORDER; PRENATAL EXPOSURE; PRESCRIPTION; QT PROLONGATION; REGISTER; RISK MANAGEMENT; SEDATION; SIDE EFFECT; UNITED STATES;

EID: 1442326095     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Holmes SC, Banowska U, Mackie RM. The prescription of isotretinoin to women: is every precaution taken? British Journal of Dermatology 1998;138:450-5.
2. Lary JM, Daniel KL, Erickson JD, Roberts HE, Moore CA. The return of thalidomide: can birth defects be prevented? Drug Safety 1999;21:161-9.
3. Chave TA, Finlay AY, Knight AG. Thalidomide usage in Wales: the need to follow guidelines. British Journal of Dermatology 2001;144:310-5.